RBC Capital keeps a Buy rating and $82 price target on Cytokinetics (CYTK), saying the firm remains bullish on the stock following the ...

RBC Capital analyst Michael Carroll maintained a Hold rating on Medical Properties (MPW – Research Report) on March 7 and set a price target of ...

We recently published a list of 13 Best Defense Stocks to Buy According to Billionaires. In this article, we are going to ...

We recently published a list of 13 Best Defense Stocks to Buy According to Billionaires. In this article, we are going to ...

Investing.com -- Galderma Group AG has been downgraded by RBC Capital Markets to "sector perform" from "outperform," ...

At RBC Capital Markets, Lori Calvasina lowered her bear case for the S&P 500 to 5,600 from 5,775 by year-end based on new ...

We recently published a list of 13 Best Defense Stocks to Buy According to Billionaires. In this article, we are going to ...

We recently published a list of 13 Best Defense Stocks to Buy According to Billionaires. In this article, we are going to ...

Fintel reports that on March 7, 2025, RBC Capital initiated coverage of GH Research (NasdaqGM:GHRS) with a Outperform ...

Market forecasters at banks including JPMorgan Chase & Co. and RBC Capital Markets have also tempered bullish calls for 2025 as Trump’s tariffs stoke fears of slowing economic growth. The S&P 500 has ...

Anxiety that tariffs and government firings will torpedo growth in the world’s largest economy extended a three-week stretch ...

Fintel reports that on March 7, 2025, RBC Capital initiated coverage of Vertiv Holdings (NYSE:VRT) with a Outperform ...